Literature DB >> 29725974

The Impact of Preoperative BMI (Obesity Class I, II, and III) on the 12-Month Evolution of Patients Undergoing Laparoscopic Gastric Bypass.

Eva M Ramírez1, Omar Espinosa1, Ricardo Berrones1, Elisa M Sepúlveda1, Lizbeth Guilbert1, Miguel Solís1, Carlos Zerrweck2.   

Abstract

BACKGROUND: Whether or not the initial body mass index (BMI) influences weight loss and comorbidities improvement after bariatric surgery continues to be a matter of debate. The main reason for this is a lack of studies including obesity class I.
METHODS: Retrospective study with patients submitted to gastric bypass at a single institution. They were classified based on initial BMI (obesity class I, II, and III), and a comparative analysis of their metabolic profile (glucose, HbA1c%, C-peptide, insulin and diabetes medication), lipid profile (triglycerides, total cholesterol, HDL, LDL), and clinical data (systolic/diastolic blood pressure and cardiovascular risk) was performed at 0 and 12 months. Diabetes remission and weight loss were also analyzed.
RESULTS: Two-hundred and twenty patients were included (23 in group 1, 113 in group 2, and 84 in group 3). Initial weight, BMI, and number of patients with T2DM were statistically different in group 1; other parameters were homogenous. At 12 months, every group had similar improvement of the metabolic profile, excepting serum insulin. Diabetes remission was 57.9, 61.1, and 60% for group 1, 2, and 3. For weight loss, there were differences between groups when using BMI and percentage of excess weight loss, but not with percentage of total weight loss. The non-metabolic and clinical data improved without differences, except for total cholesterol and LDL.
CONCLUSIONS: The metabolic, lipid, and clinical profiles associated with obesity present similar improvement 1 year after laparoscopic gastric bypass, despite different baseline BMI. Diabetes remission and percentage of total weight loss were also similar.

Entities:  

Keywords:  Bariatric surgery; Diabetes remission; Laparoscopic gastric bypass; Metabolic surgery; Obesity class I; Obesity class II; Obesity class III; Preoperative body mass index; Total weight loss

Mesh:

Year:  2018        PMID: 29725974     DOI: 10.1007/s11695-018-3281-1

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  37 in total

Review 1.  The role of gut hormones in glucose homeostasis.

Authors:  Daniel J Drucker
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 2.  The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus.

Authors:  Francesco Rubino; Lee M Kaplan; Philip R Schauer; David E Cummings
Journal:  Ann Surg       Date:  2010-03       Impact factor: 12.969

3.  Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.

Authors:  Francesco Rubino; Jacques Marescaux
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

4.  Gastric bypass increases postprandial insulin and GLP-1 in nonobese minipigs.

Authors:  R Verhaeghe; C Zerrweck; T Hubert; B Tréchot; V Gmyr; M D'Herbomez; P Pigny; F Pattou; R Caiazzo
Journal:  Eur Surg Res       Date:  2014-02-14       Impact factor: 1.745

5.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.

Authors:  Francesco Rubino; David M Nathan; Robert H Eckel; Philip R Schauer; K George M M Alberti; Paul Z Zimmet; Stefano Del Prato; Linong Ji; Shaukat M Sadikot; William H Herman; Stephanie A Amiel; Lee M Kaplan; Gaspar Taroncher-Oldenburg; David E Cummings
Journal:  Surg Obes Relat Dis       Date:  2016-07       Impact factor: 4.734

6.  How do we define cure of diabetes?

Authors:  John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

7.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.

Authors:  Francesco Rubino; David M Nathan; Robert H Eckel; Philip R Schauer; K George M M Alberti; Paul Z Zimmet; Stefano Del Prato; Linong Ji; Shaukat M Sadikot; William H Herman; Stephanie A Amiel; Lee M Kaplan; Gaspar Taroncher-Oldenburg; David E Cummings
Journal:  Diabetes Care       Date:  2016-06       Impact factor: 19.112

8.  Clinical Outcomes of Metabolic Surgery: Efficacy of Glycemic Control, Weight Loss, and Remission of Diabetes.

Authors:  Philip R Schauer; Geltrude Mingrone; Sayeed Ikramuddin; Bruce Wolfe
Journal:  Diabetes Care       Date:  2016-06       Impact factor: 19.112

9.  Improvement of type 2 diabetes mellitus (T2DM) after bariatric surgery--who fails in the early postoperative course?

Authors:  C Jurowich; A Thalheimer; D Hartmann; G Bender; F Seyfried; C T Germer; C Wichelmann
Journal:  Obes Surg       Date:  2012-10       Impact factor: 4.129

10.  Which criteria should be used to define type 2 diabetes remission after bariatric surgery?

Authors:  Ana M Ramos-Levi; Lucio Cabrerizo; Pilar Matía; Andrés Sánchez-Pernaute; Antonio J Torres; Miguel A Rubio
Journal:  BMC Surg       Date:  2013-03-28       Impact factor: 2.102

View more
  2 in total

1.  Type 2 Diabetes Mellitus Remission Models Following Laparoscopic Gastric Bypass: a 4-Model Analysis in a Latino Population.

Authors:  Antonio Herrera; Andrés León; Fátima M Rodríguez; Elisa M Sepúlveda; Lizbeth Guilbert; Omar Quiroz; Luis Cevallos; Carlos Zerrweck
Journal:  Obes Surg       Date:  2020-08-17       Impact factor: 4.129

2.  What Is Weight Loss After Bariatric Surgery Expressed in Percentage Total Weight Loss (%TWL)? A Systematic Review.

Authors:  Anne-Sophie van Rijswijk; Nienke van Olst; Winnie Schats; Donald L van der Peet; Arnold W van de Laar
Journal:  Obes Surg       Date:  2021-05-17       Impact factor: 4.129

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.